Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2701945 | 0.90 | CTSL (0.53) | CTSLCTSBCTSK | |
| Hydrochloric Acid SCHEMBL30384626 | 0.89 | CTSL (0.51) | CTSLCTSBCTSK | |
| SCHEMBL4677170 | 0.88 | TSHR (0.54) | CTSLCTSBCTSK | |
| SCHEMBL6649338 | 0.85 | TSHR (0.54) | CTSLCTSBCTSK | |
| SCHEMBL22849113 | 0.83 | AGTR2 (0.46) | AGTR2ALDH1A1CTSLCTSBCTSK | |
| SCHEMBL22835418 | 0.83 | AGTR2 (0.46) | AGTR2ALDH1A1CTSLCTSBCTSK | |
| SCHEMBL1928095 | 0.81 | TSHR (0.58) | CTSLCTSBCTSK | |
| SCHEMBL17019782 | 0.81 | TSHR (0.58) | CTSLCTSBCTSK | |
| SCHEMBL25982461 | 0.81 | DRD2 (0.46) | CTSLCTSBCTSK | |
| SCHEMBL22849511 | 0.79 | ALDH1A1 (0.55) | AGTR2NPC1RAB9AALDH1A1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539295-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250333417-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4620470-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4615455-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-20250059164-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| WO-2024264017-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| US-12150995-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240383887-A1 | DEUTERATED IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-11-21 | — | — | US | disclosed |
| US-20240316004-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | KYMERA THERAPEUTICS, INC. | 2024-09-26 | — | — | US | disclosed |
| US-11591332-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| EP-4076520-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022087216-A1 | DOUBLE DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220054453-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | KYMERA THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| WO-2022027058-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | KYMERA THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| WO-2021127190-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127283-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | AGTR2 2106/4885NPC1 3159/4885RAB9A 4270/4885 |
| US-11591332-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | AGTR2 2106/4885NPC1 3159/4885RAB9A 4270/4885 |
| US-12539295-B2 | IRAK degraders and uses thereof | IRAK2, IRAK4, IRAK3 | AGTR2 181/4885NPC1 851/4885RAB9A 4538/4885 |
| US-20220054453-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | IRAK4, IRAK2, IRAK3 | AGTR2 4295/4885NPC1 1184/4885RAB9A 3598/4885 |
| US-20240383887-A1 | DEUTERATED IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK1, IRAK3 | AGTR2 3505/4885NPC1 3665/4885RAB9A 3349/4885 |
| US-12150995-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | AGTR2 2106/4885NPC1 3159/4885RAB9A 4270/4885 |
| US-20250059164-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | AGTR2 2106/4885NPC1 3159/4885RAB9A 4270/4885 |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | AGTR2 2106/4885NPC1 3159/4885RAB9A 4270/4885 |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | AGTR2 2106/4885NPC1 3159/4885RAB9A 4270/4885 |
| US-20240316004-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | IRAK4, IRAK2, IRAK3 | AGTR2 4295/4885NPC1 1184/4885RAB9A 3598/4885 |
| US-20250333417-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | AGTR2 2106/4885NPC1 3159/4885RAB9A 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.